Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 16, 2007 - Issue 12
Submit an article Journal homepage
534
Views
120
CrossRef citations to date
0
Altmetric
Review

Natural antioxidants in Alzheimer's disease

Cesare Mancuso Catholic University School of Medicine, Institute of Pharmacology, Largo F Vito, 00168 Roma, Italy
, MD PhD,
Timothy E Bates University of Nottingham, School of Biomedical Sciences, Nottingham NG7 2UH, UK
, PhD,
D Allan Butterfield University of Kentucky, Department of Chemistry, Lexington, KY 40506, USA
, PhD,
Stella Calafato University of Catania, Section of Biochemistry and Molecular Biology, Department of Chemistry, Faculty of Medicine, Viale Andrea Doria 6, 95100 Catania, Italy +39 095 738 4067; +39 095 580138; [email protected]
, MD,
Carolin Cornelius University of Catania, Section of Biochemistry and Molecular Biology, Department of Chemistry, Faculty of Medicine, Viale Andrea Doria 6, 95100 Catania, Italy +39 095 738 4067; +39 095 580138; [email protected]
, PhD,
Antonino De Lorenzo University of Tor Vergata, Department of Neuroscience, Division of Human Nutrition,Rome, Italy
, MD,
Albena T Dinkova Kostova Johns Hopkins University School of Medicine, Division of Clinical Pharmacology, Departments of Medicine and Pharmacology and Molecular Sciences, Baltimore, MD 21205, USA
, PhD &
Vittorio Calabrese University of Catania, Section of Biochemistry and Molecular Biology, Department of Chemistry, Faculty of Medicine, Viale Andrea Doria 6, 95100 Catania, Italy +39 095 738 4067; +39 095 580138; [email protected]
, MD PhD show all
Pages 1921-1931 | Published online: 28 Nov 2007

Bibliography

  • WILSON RS, McCANN JJ, LI Y, AGGARWAL NT, GILLEY DW, EVANS DA: Nursing home placement, day care use, and cognitive decline in Alzheimer's disease. Am. J. Psychiatry (2007) 164(6):910-915.
  • BUTTERFIELD DA, REED T, NEWMAN SF, SULTANA R: Roles of amyloid β-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. (2007) 43(5):658-677.
  • MANCUSO C, SCAPAGNINI G, CURRÒ' D et al.: Mitochondrial dysfunction, free radical generation and cellular stress response in neurodegenerative disorders. Front. Biosci. (2007) 12:1107-1123.
  • CALABRESE V, SULTANA R, SCAPAGNINI G et al.: Nitrosative stress, cellular stress response, and thiol homeostasis in patients with Alzheimer's disease. Antioxid. Redox Signal. (2006) 8(11-12):1975-1986.
  • THOMPSON PM, HAYASHI KM, DUTTON RA et al.: Tracking Alzheimer's disease. Ann. NY Acad. Sci. (2007) 1097:183-214.
  • GIACOBINI E: Cholinergic function and Alzheimer's disease. Int. J. Geriatr. Psychiatry (2003) 18(Suppl. 1):S1-S5.
  • ROSSOR MN, SVENDSEN C, HUNT SP, MOUNTJOY CQ, ROTH M, IVERSEN LL: The substantia innominata in Alzheimer's disease: an histochemical and biochemical study of cholinergic marker enzymes. Neurosci. Lett. (1982) 28(2):217-222.
  • FARLOW MR, CUMMINGS JL: Effective pharmacologic management of Alzheimer's disease. Am. J. Med. (2007) 120(5):388-397.
  • McGEER PL, SCHULZER M, McGEER EG: Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology (1996) 47(2):425-432.
  • McGEER PL, McGEER EG: NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol. Aging (2007) 28(5):639-647.
  • RAMASSAMY C: Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur. J. Pharmacol. (2006) 545(1):51-64.
  • PETTEGREW JW, LEVINE J, MCCLURE RJ: Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol. Psychiatry (2000) 5(6):616-632.
  • McKHANN G, DRACHMAN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology (1984) 34(7):939-944.
  • KATZMAN R, SAITOH T: Advances in Alzheimer's disease. FASEB J. (1991) 5(3):278-286.
  • MOTT RT, HULETTE CM: Neuropathology of Alzheimer's disease. Neuroimaging Clin. North Am. (2005) 15(4):755-765.
  • BUTTERFIELD DA, LAUDERBACK CM: Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid b-peptide-associated free radical oxidative stress. Free Radic. Biol. Med. (2002) 32(11):1050-1060.
  • BUTTERFIELD DA, DRAKE J, POCERNICH C, CASTEGNA A: Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide. Trends Mol. Med. (2001) 7(12):548-554.
  • LAUDERBACK CM, HACKETT JM, HUANG FF et al.: The glial glutamate transporter, GLT-1, is oxidatively modified by 4-hydroxy-2-nonenal in the Alzheimer's disease brain: the role of Ab1-42. J. Neurochem. (2001) 78(2):413-416.
  • BUTTERFIELD DA, GRIFFIN S, MUNCH G, PASINETTI GM: Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J. Alzheimers Dis. (2002) 4(3):193-201.
  • VARADARAJAN S, YATIN S, AKSENOVA M, BUTTERFIELD DA: Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. (2000) 130(2-3):184-208.
  • YATIN SM, VARADARAJAN S, BUTTERFIELD DA: Vitamin E prevents Alzheimer's Amyloid β-peptide (1 – 42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis. (2000) 2(2):123-131.
  • SUBRAMANIAM R, KOPPAL T, GREEN M et al.: The free radical antioxidant vitamin E protects cortical synaptosomal membranes from amyloid b-peptide(25 – 35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease. Neurochem. Res. (1998) 23(11):1403-1410.
  • SMITH MA, HARRIS PL, SAYRE LM, PERRY G: Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA (1997) 94(18):9866-9868.
  • SMITH MA, PERRY G: Free radical damage, iron, and Alzheimer's disease. J. Neurol. Sci. (1995) 134(Suppl.):92-94.
  • SMITH MA, RICHEY PL, TANEDA S et al.: Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease. Ann. NY Acad. Sci. (1994) 738:447-454.
  • GASIC-MILENKOVIC J, DUKIC-STEFANOVIC S, DEUTHER-CONRAD W, GARTNER U, MUNCH G: β-amyloid peptide potentiates inflammatory responses induced by lipopolysaccharide, interferon-γ and ‘advanced glycation endproducts’ in a murine microglia cell line. Eur. J. Neurosci. (2003) 17(4):813-821.
  • HULL M, LIEB K, FIEBICH BL: Pathways of inflammatory activation in Alzheimer's disease: potential targets for disease modifying drugs. Curr. Med. Chem. (2002) 9(1):83-88.
  • KISH SJ: Brain energy metabolizing enzymes in Alzheimer's disease: α-ketoglutarate dehydrogenase complex and cytochrome oxidase. Ann. NY Acad. Sci. (1997) 826:218-228.
  • SULLIVAN PG, BROWN MR: Mitochondrial aging and dysfunction in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry (2005) 29(3):407-410.
  • MANCZAK M, PARK BS, JUNG Y, REDDY PH: Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med. (2004) 5(2):147-162.
  • BUTTERFIELD DA, POON HF, ST CLAIR D et al.: Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease. Neurobiol. Dis. (2006) 22(2):223-232.
  • KELLER JN, SCHMITT FA, SCHEFF SW et al.: Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology (2005) 64(7):1152-1156.
  • BUTTERFIELD DA, REED TT, PERLUIGI M et al.: Elevated levels of 3-nitrotyrosine in brain from subjects with amnestic mild cognitive impairment: implications for the role of nitration in the progression of Alzheimer's disease. Brain Res. (2007) 1148:243-248.
  • LUTH HJ, HOLZER M, GERTZ HJ, ARENDT T: Aberrant expression of nNOS in pyramidal neurons in Alzheimer's disease is highly co-localized with p21ras and p16INK4a. Brain Res. (2000) 852(1):45-55.
  • GARTNER U, HOLZER M, ARENDT T: Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience (1999) 91(1):1-5.
  • WENZEL E, SOMOZA V: Metabolism and bioavailability of trans-resveratrol. Mol. Nutr. Food Res. (2005) 49(5):472-481.
  • GESCHER AJ, STEWARD WP: Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev. (2003) 12(10):953-957.
  • BAUR JA, SINCLAIR DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. (2006) 5(6):493-506.
  • WALLE T, HSIEH F, DELEGGE MH, OATIS JE Jr, WALLE UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. (2004) 32(12):1377-1382.
  • SOLEAS GJ, ANGELINI M, GRASS L, DIAMANDIS EP, GOLDBERG DM: Absorption of trans-resveratrol in rats. Methods Enzymol. (2001) 335:145-154.
  • JANNIN B, MENZEL M, BERLOT JP, DELMAS D, LANCON A, LATRUFFE N: Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem. Pharmacol. (2004) 68(6):1113-1118.
  • ZHOU S, KOH HL, GAO Y, GONG ZY, LEE EJ: Herbal bioactivation: the good, the bad and the ugly. Life Sci. (2004) 74(8):935-968.
  • CAO Z, LI Y: Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur. J. Pharmacol. (2004) 489(1-2):39-48.
  • ASENSI M, MEDINA I, ORTEGA A et al.: Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. (2002) 33(3):387-398.
  • KIM YA, LIM SY, RHEE SH et al.: Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells. Int. J. Mol. Med. (2006) 17(6):1069-1075.
  • ANEKONDA TS: Resveratrol – a boon for treating Alzheimer's disease? Brain Res. Rev. (2006) 52(2):316-326.
  • JANG JH, SURH YJ: Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death. Free Radic. Biol. Med. (2003) 34(8):1100-1110.
  • HAN YS, ZHENG WH, BASTIANETTO S, CHABOT JG, QUIRION R: Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br. J. Pharmacol. (2004) 141(6):997-1005.
  • MARAMBAUD P, ZHAO H, DAVIES P: Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides. J. Biol. Chem. (2005) 280(45):37377-37382.
  • BASTIANETTO S, ZHENG WH, QUIRION R: Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons. Br. J. Pharmacol. (2000) 131(4):711-720.
  • SHARMA M, GUPTA YK: Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats. Life Sci. (2002) 71(21):2489-2498.
  • ANEKONDA TS, REDDY PH: Neuronal protection by sirtuins in Alzheimer's disease. J. Neurochem. (2006) 96(2):305-313.
  • CALABRESE V, GUAGLIANO E, SAPIENZA M et al.: Redox regulation of cellular stress response in aging and neurodegenerative disorders: role of vitagenes, Neurochem. Res. (2007) 32(4-5):757-773.
  • CALABRESE V, MANCUSO C, CALVANI M, RIZZARELLI E, BUTTERFIELD DA, STELLA AM: Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity. Nat. Rev. Neurosci. (2007) 8(10):766-775.
  • CALABRESE V, BOYD-KIMBALL D, SCAPAGNINI G, BUTTERFIELD DA: Nitric oxide and cellular stress response in brain aging and neurodegenerative disorders: the role of vitagenes. In Vivo (2004) 18:245-267.
  • CALABRESE V, BUTTERFIELD DA, SCAPAGNINI G, STELLA AM, MAINES MD: Redox regulation of heat shock protein expression by signaling involving nitric oxide and carbon monoxide: relevance to brain aging, neurodegenerative disorders, and longevity, Antioxid. Redox Signal. (2006) 8(3-4):444-477.
  • MANCUSO C, PANI G, CALABRESE V: Bilirubin: an endogenous scavenger of nitric oxide and reactive nitrogen species. Redox Rep. (2006) 11(5):207-213.
  • MANCUSO C: Heme oxygenase and its products in the nervous system. Antioxid. Redox Signal. (2004) 6(5):878-887.
  • STOCKER R: Antioxidant activities of bile pigments. Antioxid. Redox Signal. (2004) 6(5):841-849.
  • CHEN CY, JANG JH, LI MH, SURH YJ: Resveratrol upregulates heme oxygenase-1 expression via activation of NF-E2-related factor 2 in PC12 cells. Biochem. Biophys. Res. Commun. (2005) 331(4):993-1000.
  • ZHUANG H, KIM YS, KOEHLER RC, DORE S: Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann. NY Acad. Sci. (2003) 993:276-286.
  • TAKAHASHI M, DORE S, FERRIS CD et al.: Amyloid precursor proteins inhibit heme oxygenase activity and augment neurotoxicity in Alzheimer's disease. Neuron (2000) 28(2):461-473.
  • TAKEDA A, PERRY G, ABRAHAM NG et al.: Overexpression of heme oxygenase in neuronal cells, the possible interaction with τ. J. Biol. Chem. (2000) 275(8):5395-5399.
  • RAHMAN I, BISWAS SK, KIRKHAM PA: Regulation of inflammation and redox signaling by dietary polyphenols. Biochem. Pharmacol. (2006) 72(11):1439-1452.
  • TIRKEY N, KAUR G, VIJ G, CHOPRA K: Curcumin, a diferuloylmethane, attenuates cyclosporine-induced renal dysfunction and oxidative stress in rat kidneys. BMC Pharmacol. (2005) 5:15.
  • CHEN J, TANG XQ, ZHI JL et al.: Curcumin protects PC12 cells against 1-methyl-4-phenylpyridinium ion-induced apoptosis by bcl-2-mitochondria-ROS-iNOS pathway. Apoptosis (2006) 11(6):943-953.
  • DIVYA CS, PILLAI MR: Antitumor action of curcumin in human papillomavirus associated cells involves downregulation of viral oncogenes, prevention of NFkB and AP-1 translocation, and modulation of apoptosis. Mol. Carcinog. (2006) 45(5):320-332.
  • PEREZ-ARRIAGA L, MENDOZA-MAGANA ML, CORTES-ZARATE R et al.: Cytotoxic effect of curcumin on Giardia lamblia trophozoites. Acta Trop. (2006) 98(2):152-161.
  • RAMSEWAK RS, DEWITT DL, NAIR MG: Cytotoxicity, antioxidant and anti-inflammatory activities of curcumins I – III from Curcuma longa. Phytomedicine (2000) 7(4):303-308.
  • MEHTA K, PANTAZIS P, MCQUEEN T, AGGARWAL BB: Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs (1997) 8(5):470-481.
  • SHARMA RA, GESCHER AJ, STEWARD WP: Curcumin: the story so far. Eur. J. Cancer (2005) 41(13):1955-1968.
  • RAVINDRANATH V, CHANDRASEKHARA N: Metabolism of curcumin – studies with [3H]curcumin. Toxicology (1981 – 1982) 22(4):337-344.
  • RAVINDRANATH V, CHANDRASEKHARA N: Absorption and tissue distribution of curcumin in rats. Toxicology (1980) 16(3):259-265.
  • MAITI K, MUKHERJEE K, GANTAIT A, SAHA BP, MUKHERJEE PK: Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. (2007) 330(1-2):155-163.
  • SHOBA G, JOY D, JOSEPH T et al.: Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta. Med. (1998) 64(4):353-356.
  • CHENG AL, HSU CH, LIN JK et al.: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. (2001) 21(4B):2895-2900.
  • GARCIA-ALLOZA M, BORRELLI LA, ROZKALNE A, HYMAN B, BACSKAI BJ: Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J. Neurochem. (2007) 102(4):1095-1104.
  • SOMPARN P, PHISALAPHONG C, NAKORNCHAI S, UNCHERN S, MORALES NP: Comparative antioxidant activities of curcumin and its demethoxy and hydrogenated derivatives. Biol. Pharm. Bull. (2007) 30(1):74-78.
  • IRESON CR, JONES DJ, ORR S et al.: Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol. Biomarkers Prev. (2002) 11(1):105-111.
  • LIN JK, PAN MH, LIN-SHIA SY: Recent studies on the biofunctions and biotransformations of curcumin. Biofactors (2000) 13(1-4):153-158.
  • HAYESHI R, MUTINGWENDE I, MAVENGERE W, MASIYANISE V, MUKANGANYAMA S: The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin. Food Chem. Toxicol. (2007) 45(2):286-295.
  • THAPLIYAL R, MARU GB: Inhibition of cytochrome P450 isozymes by curcumins in vitro and in vivo. Food Chem. Toxicol. (2001) 39(6):541-547.
  • BASU NK, CIOTTI M, HWANG MS et al.: Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J. Biol. Chem. (2004) 279(2):1429-1441.
  • OETARI S, SUDIBYO M, COMMANDEUR JN, SAMHOEDI R, VERMEULEN NP: Effects of curcumin on cytochrome P450 and glutathione S-transferase activities in rat liver. Biochem. Pharmacol. (1996) 51(1):39-45.
  • SHARMA RA, EUDEN SA, PLATTON SL et al.: Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer Res. (2004) 10(20):6847-6854.
  • DEODHAR SD, SETHI R, SRIMAL RC: Preliminary study on antirheumatic activity of curcumin (diferuloyl methane). Indian J. Med. Res. (1980) 71:632-634.
  • GANGULI M, CHANDRA V, KAMBOH MI et al.: Apolipoprotein E polymorphism and Alzheimer disease: the Indo-US Cross-National dementia study. Arch. Neurol. (2000) 57(6):824-830.
  • KIM DS, PARK SY, KIM JK et al.: Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from βA(1 – 42) insult. Neurosci. Lett. (2001) 303(1):57-61.
  • LIM GP, CHU T, YANG F et al.: The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. (2001) 21(21):8370-8377.
  • ONO K, HASEGAWA K, NAIKI H, YAMADA M: Curcumin has potent anti-amyloidogenic effects for Alzheimer's β-amyloid fibrils in vitro. J. Neurosci. Res. (2004) 75(6):742-750.
  • YANG F, LIM GP, BEGUM AN et al.: Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem. (2005) 280(7):5892-5901.
  • CALABRESE V, SCAPAGNINI G, COLOMBRITA C et al.: Redox regulation of heat shock protein expression in aging and neurodegenerative disorders associated with oxidative stress: a nutritional approach. Amino Acids (2003) 25(3-4):437-444.
  • SHISHODIA S, SINGH T, CHATURVEDI MM: Modulation of transcription factors by curcumin. Adv. Exp. Med. Biol. (2007) 595:127-148.
  • JOVANOVIC SV, BOONE CW, STEENKEN S, TRINOGA M, KASKEY RB: How curcumin works preferentially with water soluble antioxidants. J. Am. Chem. Soc. (2001) 123(13):3064-3068.
  • LEE JS, SURH YJ: Nrf2 as a novel molecular target for chemoprevention. Cancer Lett. (2005) 224(2):171-184.
  • DINKOVA-KOSTOVA AT, CHEAH J, SAMOUILOV A et al.: Phenolic Michael reaction acceptors: combined direct and indirect antioxidant defenses against electrophiles and oxidants. Med. Chem. (2007) 3(3):261-268.
  • GAO X, DINKOVA-KOSTOVA AT, TALALAY P: Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. Proc. Natl. Acad. Sci. USA (2001) 98(26):15221-15226.
  • EVANS AM, FORNASINI G: Pharmacokinetics of L-carnitine. Clin. Pharmacokinet. (2003) 42(11):941-967.
  • REBOUCHE CJ: Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann. NY Acad. Sci. (2004) 1033:30-41.
  • LOMBARD KA, OLSON AL, NELSON SE, REBOUCHE CJ: Carnitine status of lactoovovegetarians and strict vegetarian adults and children. Am. J. Clin. Nutr. (1989) 50(2):301-306.
  • BRASS EP, HOPPEL CL, HIATT WR: Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. Clin. Pharmacol. Ther. (1994) 55(6):681-692.
  • GROSS CJ, SAVAIANO DA: Effect of development and nutritional state on the uptake, metabolism and release of free and acetyl-L-carnitine by the rodent small intestine. Biochim. Biophys Acta (1993) 1170(3):265-274.
  • PARNETTI L, GAITI A, MECOCCI P, CADINI D, SENIN U: Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type. Eur. J. Clin. Pharmacol. (1992) 42(1):89-93.
  • KELLY JG, HUNT S, DOYLE GD et al.: Pharmacokinetics of oral acetyl-L-carnitine in renal impairment. Eur. J. Clin. Pharmacol. (1990) 38(3):309-312.
  • MCDANIEL MA, MAIER SF, EINSTEIN GO: “Brain-specific” nutrients: a memory cure? Nutrition (2003) 19(11-12):957-975.
  • ABDUL HM, CALABRESE V, CALVANI M, BUTTERFIELD DA: Acetyl-L-carnitine-induced up-regulation of heat shock proteins protects cortical neurons against amyloid-β peptide 1 – 42-mediated oxidative stress and neurotoxicity: implications for Alzheimer's disease. J. Neurosci. Res. (2006) 84(2):398-408.
  • CALABRESE V, COLOMBRITA C, SULTANA R et al.: Redox modulation of heat shock protein expression by acetylcarnitine in aging brain: relationship to antioxidant status and mitochondrial function. Antioxid. Redox Signal. (2006) 8(3-4):404-416.
  • RAI G, WRIGHT G, SCOTT L, BESTON B, REST J, EXTON-SMITH AN: Double-blind, placebo controlled study of acetyl-l-carnitine in patients with Alzheimer's dementia. Curr. Med. Res. Opin. (1990) 11(10):638-647.
  • SPAGNOLI A, LUCCA U, MENASCE G et al.: Long-term acetyl-L-carnitine treatment in Alzheimer's disease. Neurology (1991) 41(11):1726-1732.
  • THAL LJ, CARTA A, CLARKE WR et al.: A 1-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease. Neurology (1996) 47(3):705-711.
  • THAL LJ, CALVANI M, AMATO A, CARTA A: A 1-year controlled trial of acetyl-l-carnitine in early-onset AD. Neurology (2000) 55(6):805-810.
  • CALABRESE V, RAVAGNA A, COLOMBRITA C et al.: Acetylcarnitine induces heme oxygenase in rat astrocytes and protects against oxidative stress: involvement of the transcription factor Nrf2. J. Neurosci. Res. (2005) 79:509-521.
  • TARIOT PN, FARLOW MR, GROSSBERG GT et al.: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA (2004) 291(3):317-324.
  • ZHOU S, YUNG CHAN S, CHER GOH B et al.: Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. (2005) 44(3):279-304.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.